Preparation, In Vitro characterization and stability studies of ropinirole lipid nanoparticles enriched hydrogel for treatment of neurodegeneration diseases

Abstract

Ropinirole (RP), is a selective dopamine agonist that is used alone or with other medications to treat the symptoms of Parkinson’s disease (PD). RP has low bioavailability of only about 50% due to the first-pass metabolism, and it requires frequent dosing during oral administration. The objective of the current research was to develop RP loaded solid lipid nanoparticles (RP-SLNs), nanostructured lipid carriers (RP-NLCs), and their corresponding hydrogels (RP-SLN-C and RP-NLC-C) that might improve efficacy in PD treatment. RP nanoparticles were prepared by homogenization aided probe sonication method and optimized based on particle size, polydispersity index (PDI), zeta potential (ZP), assay, entrapment efficiency, and in vitro release studies. Optimized formulations were converted to hydrogel formulations using Carbopol 934 as a gelling polymer and optimized based on rheological and release characteristics. Optimized formulations were further evaluated using differential scanning calorimetry (DSC), powder X-ray diffractometry (PXRD), scanning electron microscopy (SEM), freeze-drying, and stability study at refrigerated and room temperatures. The optimized RP-SLN formulation showed particle size and entrapment efficiency of 213.5±3.8 nm and 77.9±3.1% compared to 190.6±3.7 nm and 85.7±1.7% for optimized RP-NLC formulation. PXRD supplemented and confirmed DSC results, RP was entrapped in a molecularly dispersed state inside the core of the lipid nanocarrier. Furthermore, RP loaded lipid nanocarriers revealed a spherical shape in SEM images. In vitro release studies demonstrated sustained release profiles for RP from SLNs, NLCs, and their hydrogels over 24 h and were stable over three months at 4ºC and 25ºC storage conditions.
 Keywords: Parkinson’s disease, Ropinirole, Solid lipid nanoparticles, Nanostructured lipid carriers, Hydrogel.

Approaches to Improve Oral Bioavailability of Antihypertensive Drugs: A Mini-Review

“…Delivering drugs that have low aqueous solubility and/or permeability (BCS class II & IV) is a complicated task due to poor bioavailability caused by pH variation in the gastrointestinal tract (GIT) [34][35][36][37][38][39][40][41][42][43] . The pH difference can impact the pharmacological activity of a drug by any of the chemical degradation pathways like oxidation, deamidation, or hydrolysis of both small molecules and large molecules 44 .…”

Statistically Optimized Facile Development, Characterization and Evaluation of Niosomal Nasal Drug Delivery System of Ropinirole Hydrochloride: In vitro Drug Release, Cytotoxicity and ex vivo Permeability Studies

“…14 There has been lot of work done on ROP-HCl so far with Ethosomal formulations, Hydrogel based nanoparticles, polymer-lipid nanoparticles and chitosan coated Nanoparticles for controlled release and intranasal delivery. [15][16][17][18][19][20] The details are summarized in Table 2. The present study is unique in that it is the first instance of a Niosomal formulation of ROP-HCL being reported based on a statistically optimized method and researched for its potential Intranasal delivery and overcoming drug permeability limitations as well as investigating feasibility of nose to brain delivery route for this formulation, thereby opening new avenues in Parkinson's disease treatment.…”